You might not have to depend on Google Podcasts if you’re asking Assistant to play your favorite serialized audio show. Android Police and its readers have discovered that Google is adding support for third-party podcast services, starting with Spotify. You just have to visit podcast settings in Assistant to choose your provider.
We’ve asked Google if it can comment on the feature’s rollout. AP’s writer had trouble getting it to work, though it may be due to regional issues.
Whenever the feature is ready, it could be very useful whether you listen on your phone or an Assistant speaker like the Nest Audio. If you sync all your podcast listening in one app, this could keep your syncing intact no matter how you prefer to listen. Moreover, services like Spotify have exclusive podcasts that simply aren’t accessible if you rely on Assistant to reach them quickly. This opens the door to playing what you want without having to launch an app on your phone.
What’s more critical for the stock market’s health than the outcome of the presidential election? A COVID-19 vaccine, so says Goldman Sachs. With Q3 earnings season kicking into gear this week, the firm believes the virus’ effect on fundamentals should be the focus, as opposed to the race to the White House. “The vaccine represents a more important factor than the election result for the path of equities… The consequences of the semi-frozen economy on an uneven road to recovery will be in Q3 results,” Goldman Sachs’ U.S. equity strategist David Kostin commented. Even though elections are a source of uncertainty, research analysts from Goldman Sachs found just a 4% difference in EPS if President Trump is re-elected or the Democrats come out on top. Based on the firm’s analysis, an increase in fiscal spending that is partly funded by increased tax revenue would “boost economic growth, and help offset the earnings headwind from high tax rates.” Taking this into consideration, our attention turned to two stocks that Goldman Sachs thinks have outsized growth prospects, with the firm’s analysts forecasting at least 90% upside potential for each. Using TipRanks’ database, we found out both tickers also sport a “Strong Buy” consensus rating from the rest of the Street. Athira Pharma (ATHA) Applying cutting-edge approaches to neurodegenerative diseases, Athira Pharma wants to improve the lives of patients from all over the world. Given the potential of its asset in Alzheimer’s disease (AD), Goldman Sachs is pounding the table. ATHA made its public market debut on September 18, with the first trade coming in at 17.4% above the IPO price. Raising $204 million, the company sold 12 million shares instead of the 10 million that was originally expected. Writing for Goldman Sachs, analyst Graig Suvannavejh points to its lead candidate, ATH-1017, which is a small molecule activator of HGF/MET currently being evaluated in a Phase 2/3 trial as a treatment for mild-to-moderate AD, as a key component of his bullish thesis. The analyst doesn’t dispute that AD is a difficult indication to address, but tells clients he has high hopes for ATHA. “We’re fully cognizant of the history of AD drug development, and its well documented past of high failure rates. As such, AD-focused companies like ATHA should be considered as having high risk. However, as there still remains a significant lack of effective drugs for AD, we believe alternative approaches to treating AD have merit,” he explained. In the past, the most common therapeutic approaches to AD have been those focused on the belief that the accumulation of disease-causing proteins in the brain leads to AD. However, AD therapeutics based on targeting amyloid have all failed in clinical trials to demonstrate efficacy, with monoclonal antibody (mAb) approaches that target tau, another protein that aggregates in the brains of AD patients, also failing. So, ATHA’s differentiated approach makes it a stand-out, in Suvannavejh’s opinion. Looking at the therapy’s mechanism of action (MOA), it is based on HGF/MET agonism, a strategy that hasn’t been studied in AD before. Additionally, Suvannavejh argues the FDA’s recent decision to review Biogen’s aducanumab for approval even though it was prematurely discontinued in two large Phase 3 studies due to futility is a “sign of a positive regulatory backdrop.” On top of this, the company is applying a new thinking to AD clinical trials. It will use a non-traditional technique (EEG) in order to measure improvements in the brains of AD subjects, and a novel clinical trial end point (Global Statistical Test/GST) that will evaluate the efficacy. It is based on both the ERP biomarker and more traditional efficacy measures (e.g., ADAS-Cog). Weighing in on this, Suvannavejh stated, “With this entirely innovative way of thinking in mind, we think it’s critical to acknowledge that FDA has already provided its sign off to ATHA’s novel clinical trial plan — which importantly also reduces overall time and costs typically associated with AD drug development. Further, given our view that FDA may be experiencing a sense of urgency to get new AD therapeutics in the hands of patients, their caregivers and physicians, we believe the time is right for a candidate like ATH-1017.” When it comes to the revenue potential for ATH-1017, according to Suvannavejh, neurodegenerative diseases represent one of the highest areas of unmet medical need, with it estimated that more than 5 million people over the age of 65 in the U.S. have AD. This number is expected to nearly triple by 2050, based on research from the Alzheimer’s Association. To this end, the analyst projects risk-unadjusted peak 2035 sales of $10.8 billion. Everything that ATHA has going for it convinced Suvannavejh to initiate coverage with a Buy rating. In addition to the call, he set a $53 price target, suggesting 189% upside potential. (To watch Suvannavejh’s track record, click here) Judging by the consensus breakdown, opinions are anything but mixed. With 4 Buys and no Holds or Sells assigned in the last three months, the word on the Street is that ATHA is a Strong Buy. At $42.50, the average price target implies 132% upside potential. (See Athira Pharma stock analysis on TipRanks) Denali Therapeutics (DNLI) Dedicated to defeating neurodegenerative diseases through rigorous therapeutic development, Denali Therapeutics is attracting significant attention from Wall Street. Ahead of a key data readout, Goldman Sachs has high hopes. As the company gears up to report first proof-of-concept biomarker data for DNL310 in Hunter syndrome by YE20, the firm’s Salveen Richter likes what she’s seeing. DNL310 is a recombinant form of the iduronate 2-sulfatase (IDS) enzyme engineered to cross the blood-brain barrier (BBB) using Denali’s enzyme transport vehicle (ETV) technology, which enables the trafficking of large molecules into the brain. DNLI is set to publish initial data from Cohort A, and management expects the starting dose of 3mg/kg to reduce CSF GAGs by 50% at eight weeks. A second Cohort B will evaluate DNL310 in a broader range of patients, with dose escalation levels based on findings from Cohort A. Richter points out a 50% reduction in CSF GAGs was associated with a decrease in lipid lysosome and neurofilament light (NfL) chain accumulations that are associated with neuronal degeneration and injury. “While this is the first in-human trial for DNL310, we see the pre-clinical data as strongly supportive of the anticipated therapeutic benefit and potential for GAG reduction in the CSF to drive downstream changes in lysosomal lipid and NfL accumulation (i.e. prevent neuronal dysfunction and injury) for improved cognition and function,” Richter commented. It should be noted that the preclinical and early clinical data for JCR Pharmaceuticals’ JR-141, a BBB-penetrant fusion protein that also leverages receptor-mediated transcytosis to traffic iduronate-2-sulfatase (I2S) to the brain, de-risks the approach, in Richter’s opinion. To this end, the five-star analyst believes positive DNL310 biomarker data could serve as proof-of-concept for DNLI’s transport vehicle (TV) technology. The platform’s modularity could allow for various large molecules to be transported across the BBB, for a range of other neurodegenerative indications like Parkinson’s disease (PD) and frontotemporal dementia (FTD). On top of this, DNLI could leverage this delivery platform for antibodies, proteins or enzymes not currently in its own portfolio, with increasing interest on assets from Biogen, according to Richter. In line with her optimistic approach, Richter stayed with the bulls, reiterating a Buy rating. She also bumped up the price target from $41 to $60. Investors could be pocketing a gain of 36%, should this target be met in the twelve months ahead. (To watch Richter’s track record, click here) Looking at the consensus breakdown, 6 Buys and 2 Holds have been issued in the last three months. Therefore, DNLI gets a Strong Buy consensus rating. Based on the $51.17 average price target, shares could surge 16% in the next year. (See Denali Therapeutics stock analysis on TipRanks) Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
The stock market rally is at a turning point; here’s what investors should be doing. House Speaker Nancy Pelosi set a pre-election stimulus deal deadline.
The biggest power players on Wall Street have already seen it coming – and quietly changed their outlook for 2021. This will affect your money.
My wife and I co-signed her nephew’s student loans so he could attend a small private college. You loaned money to your nephew by co-signing his loan with the expectation that he would finish college, get a job and repay it. In other words, you co-signed the loan so your nephew would make the investment in his own future.
The 33rd anniversary of the « Black Monday » market crash is upon us, and if hedge-fund managers are scared of history repeating itself, you wouldn’t know if from the massive overhaul in their positions over the past week.
Earnings season is set to pick up this week, giving investors a better picture of the state of corporate profitability amid the ongoing coronavirus pandemic.
Global research firm just identified a stock with the potential to « crush Zoom’s gains. » Click here to see which stock they’re recommending.
(Bloomberg) — Hedge funds have pulled back from one of the biggest short positions in U.S. tech stocks in over a decade, in a near-record buying spree of Nasdaq futures last week.Net speculative positions in Nasdaq 100 mini contracts surged by the most in more than 13 years in the week through Oct. 13, according to the latest Commodity Futures Trading Commission data. The increase was the second biggest on record in data going back to 1999 and left speculators net long the futures for the first time since the beginning of last month.The buying frenzy comes after fast-money accounts had driven net short bets to the highest since before the financial crisis during September.The U.S. tech gauge has risen over 9% from its Sept. 23 low amid signs of a return of bullish options activity that helped push it to an all-time high earlier that month. It remains about 5% below that record.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Intel (INTC) stock struggled during the third quarter, with disappointed investors hitting the exits at a rapid pace.
Hexavest of Montreal more than halved its investment in AT&T stock, and cut about a third from positions in Newmont and Barrick Gold in the third quarter. It also initiated a position in Wells Fargo stock.
While investors are obsessed with Tesla’s surge, legendary investor Whitney Tilson says an even bigger EV story will provide the highest gains.
Buying a stock is easy, but buying the right stock without a time-tested strategy is incredibly hard. So what are the best stocks to buy now or put on a watchlist?
Out on Wall Street, things are always changing. Share prices fluctuate, new players make their market debuts, the macro environment gets shaken up and long-term trends shift. That said, one thing remains the same: growth is the name of the game. Growth stocks consistently score a spot on investors’ wish lists, given their potential to deliver returns. This growth potential goes above and beyond the norm, as these plays have already posted some spectacular gains in 2020, with the upside set to keep on coming in the long run. Knowing what you’re looking for is one thing, but how are investors supposed to find these opportunities? One strategy is to take a cue from Wall Street pros. Bearing this in mind, we used TipRanks’ database during our search for exciting growth names, according to the analyst community. Locking in on three stocks that fit the bill, each analyst-backed ticker stands to notch more gains on top of their impressive year-to-date climbs. Here are all of the details. Sunnova Energy International (NOVA) First up we have Sunnova Energy International, which is one of the top providers of residential solar and energy storage services. Even though it has already jumped 160% year-to-date, several analysts think this name has more room to run. After speaking with NOVA’s founder and CEO John Berger, five-star analyst Joseph Osha, of JMP Securities, is even more confident in its long-term growth prospects, noting the “stock appears significantly undervalued.” Highlighting the storage business in particular, the analyst believes it is a major point of strength. “NOVA has been effective at driving storage attach rates higher, and has managed to make its dealer-focused business model perform well. The demand environment for storage has strengthened during the last 60 days, and we believe that we may be at an inflection point for the industry,” Osha commented. Looking more closely at attach rates, the figure landed at 34% in Q2. Part of this strong result was driven by the company’s move into island markets, with Berger mentioning that the attach rates in Hawaii, Guam, Saipan and Puerto Rico are effectively 100%. Additionally, rates are improving in Texas and Florida. Expounding on this, Osha stated, “Aggregating all of that together yields a 34% number that Mr. Berger believes is going to grow, albeit with very different dynamics in different markets. We also note that NOVA is selling storage to existing customers, and those sales are not reflected in the stated attach rate.” Reflecting more positives, Osha says NOVA’s relationships with Tesla and Generac set it apart, with it also choosing the ideal dealer partners. What’s more, the overall storage market appears solid, and cell manufactures are struggling to keep up with the demand. To this end, Berger argues the space is “as strong as you think it would be with attach rates continuing to rise in new geographies and revenue per customer growing as well.” While some investors have brought up concerns regarding competition from Sunrun (RUN), Osha thinks that even though RUN’s approach is working relatively well, the “smaller developers may lose out” in the end. As a result, the analyst sees room for a larger valuation for NOVA. In line with his optimistic approach, Osha stayed with the bulls, reiterating a Market Outperform rating and $43 price target. Investors could be pocketing a gain of 48%, should this target be met in the twelve months ahead. (To watch Osha’s track record, click here) Are other analysts in agreement? They are. Only Buy ratings, 10 to be exact, have been issued in the last three months. Therefore, the message is clear: NOVA is a Strong Buy. Given the $33.70 average price target, shares could surge 16% in the next year. (See Sunnova Energy International stock analysis on TipRanks) Big Lots (BIG) As a closeout retailer, Big Lots offers its customers everything from groceries and household essentials to furniture and electronics at an affordable price. With a solid standing going into 2021, some members of the Street believe its 87% year-to-date gain is only the beginning. Representing Piper Sandler, five-star analyst Peter Keith tells clients that going forward, “the set-up remains highly favorable.” The company’s guidance for Q3 comps was above his estimate, but the call for EPS of $0.50-$0.70 (versus Keith’s $0.12 forecast) was a major surprise. “Not only has Q3 historically been a negative EPS quarter, but also BIG is guiding huge EPS upside despite ~$12 million of incremental rent expense (from selling its DC’s) and ~$10 million of COVID expenses,” Keith noted. To this end, the analyst bumped up his Q4 comp estimate. Keith explained, “Q4 is setting up to be quite strong, the move back into discretionary closeouts couldn’t be better timed, our survey work continues to show elevated demand for home furnishings, and any positive impact from the new Chief Merchant (who joined in late July) has not yet impacted the sales trend.” When it comes to closeout activity, new CMO Jack Pestello has helped strengthen BIG’s efforts in closeouts, with Keith already noticing compelling offerings during store checks. Additionally, the reduction of promos should bode well for the retailer. BIG has cut the number of promo days in half in Q3 2020, when compared to Q3 2019. Therefore, although BIG is guiding for flattish gross margins year-over-year, there is room for upside, in Keith’s opinion. On top of this, its inventory position could be on the mend. According to management, most categories have had some inventory constraints in Q3, but vendors are catching up with demand, especially in key segments like furniture, home office and small appliances. Adding to the good news, a $500 million share repurchase authorization was announced, which Keith argues should “add some juice to EPS over the coming quarters.” Everything that BIG has going for it convinced Keith to maintain his Overweight rating. In addition to the call, he left the price target at $75, suggesting 40% upside potential. (To watch Keith’s track record, click here) Turning to the rest of the Street, opinions are split evenly. With 3 Buys and 3 Holds assigned in the last three months, the word on the Street is that BIG is a Moderate Buy. At $60.33, the average price target implies 12% upside potential. (See Big Lots stock analysis on TipRanks) Amicus Therapeutics (FOLD) Last but not least we have Amicus Therapeutics, which develops therapies for ultra-orphan diseases, including lysosomal storage disorders (LSDs). Up 77% year-to-date, even more growth could be on tap for this healthcare name, so says multiple Street pros. Even though it boasts a next generation enzyme replacement therapy in Phase 3, one of its gene therapy assets has received significant attention. During the CNSA conference, FOLD presented additional follow-up data from its Phase 1/2 CLN6 Battens gene therapy program. The program is evaluating AT-GTX-501, its gene therapy designed for use in CLN6 Batten disease, which is a fatal condition where children experience rapid and progressive decline in cognitive and motor function. It has a worldwide population of roughly 1,000 patients. The presentation included incremental interim safety and efficacy data. Based on the safety data for 13 patients treated with the candidate, the therapy was well tolerated. It should be noted that five patients reported eleven Grade 3 SAEs, including four that were considered to be potentially treatment-related. These included vomiting, fever and upper abdominal pain, which are symptoms frequently seen with AAV gene therapy administration. Weighing in for Cowen, five-star analyst Ritu Baral argues the fact that immunogenicity to AAV9 or CLN6 was not observed is an important takeaway. As for the efficacy data, the results for twelve patients that reached the 12-month timepoint and eight that hit the 24-month timepoint were analyzed against age-matched natural history. On the Hamburg Motor and Language (HM&L) Aggregate score, which assesses ambulation and speech, the mean rate of decline in treated patients was much lower compared to natural history over the same time period. Digging a bit deeper, at the 12-month timepoint, the mean rate of decline in treated subjects was 0.4 points, versus 1.2 points in natural history subjects. At the 24-month timepoint, the mean rate of decline was 0.6 points in treated subjects, compared to 2.4 points in the natural history participants. What’s more, management stated that 63% of natural history patients saw an additional 2-point drop on the HM&L score two years after their first decline, while only 13% of AT-GTX-501 gene therapy recipients experienced the same. What does all of this mean? “We think this update is incrementally positive and demonstrates the durability of AT-GTX-501’s efficacy out to two years. Interim efficacy results show nominally statistically significant and very likely clinically meaningful slowing of disease progression over 24 months in CLN6 Battens… The natural history dataset was collected was a relatively recent chart review by the same investigator as the FOLD study, and therefore we believe is likely reliable,” Baral commented. If that wasn’t enough, the natural history control analysis could be enough for U.S. registration. “We believe given the rarity and severity of CLN6, that a prospective PBO controlled trial is not feasible. We believe the natural history data in the disease is rapidly solidifying into a body of evidence that will be meaningful to both FDA and EMA,” Baral explained. Given all of the above, Baral has high hopes. Along with an Outperform rating, she keeps a $31 price target on the stock. This target puts the upside potential at 81%. (To watch Baral’s track record, click here) Other analysts seem to echo Baral’s sentiment. 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Based on the average price target of $23.67, the upside potential comes in at 38%. (See Amicus Therapeutics stock analysis on TipRanks) Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
While many FIRE pursuants look to become landlords for the steady income and growth potential, a high bar to entry means property ownership isn’t for everyone. Real estate investment trusts can be a good alternative.
If you have good credit, you can get up to $50,000 cash in one lump sum. Repay monthly. No Collateral Required. Takes 2 minutes to qualify.
Mortgage rates fall to a new all-time low supporting the real estate sector. As a result, dire labor market conditions have yet to hit home-buyer demand.
The Indian government has warned Amazon.com’s local unit and Walmart’s Flipkart that sellers on their platforms are not complying with a rule requiring that a product’s country of origin be specified. A push for strict enforcement of the rule has come amid tensions between India and China following a border skirmish which began in June, and is part of India’s efforts to cut down on Chinese-made imports. Representatives for Amazon and Flipkart did not immediately respond to Reuters requests seeking comment outside regular business hours.
Apple, Amazon.com and Microsoft headline five top tech stocks that are close to finishing a classic bullish base that will offer them lower buy points.
Compare 2020 top lenders to get matched with lenders curated for your needs in 2 min. A+ Rating with BBB. Over 15 million served since 2005. 2.39% APR
Asian markets advanced toward a recent 2-1/2-year peak on Monday powered by hopes of a U.S fiscal package and expectations of a coronavirus vaccine by the end of this year, though weaker-than-expected Chinese data capped gains. MSCI’s broadest index of Asia-Pacific shares outside Japan climbed 0.6% for its second straight day of gains, paring back slightly following third-quarter gross domestic product data from China.
* Insider buying can be an encouraging signal for potential investors when markets face uncertainty. * More initial public offerings encouraged insiders to buy shares last week. * Insiders also have bought into a big bank, an asset manager and a cruise operator.Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when markets are near all-time highs.Insiders continued to add shares despite market volatility and economic uncertainty. Here are some of the most noteworthy insider purchases reported in the past week.Biotechnology company Shattuck Labs Inc (NASDAQ: STTK) saw beneficial owner Redmile Group step up to the buy window after the initial public offering. At $17.00 to $22.10 per share, the more than 3.44 million shares totaled nearly $59.66 million. Shares closed Friday’s trading at $20.00, down from a post-IPO high of $22.90 seen on the first day of trading.Last week, a Brookfield Asset Management Inc (NYSE: BAM) director added almost 2.13 million shares at $15.00 apiece. That totaled more than $31.94 million and brought the stake to over 17.45 million shares. Note that this director also purchased around 21,000 shares of this Toronto-based alternative asset manager back in early September.Kronos Bio Inc (NASDAQ: KRON) had CEO Norbert Bischofberger and some other executives and directors take advantage of the initial public offering to buy more than 639,600 shares altogether at $19.00 apiece. Those transactions totaled more than $12.15 million. Bischofberger’s 95,500 shares were acquired via trust, and the stock ended last week at $32.06 per share.The executive board chair at Fubotv Inc (NYSE: FUBO), Edgar Miles Bronfman Jr., indirectly purchased 200,000 shares of TV streaming platform for the public offering price of $10.00 apiece. Another director also added 200,000 shares last week. That cost them $4.00 million altogether. The share price rose nearly 19% in the past week to close at $12.01 on Friday.The chief financial officer, another executive and a director added a combined 102,000 or so Gossamer Bio Inc (NASDAQ: GOSS) shares to their stakes last week. Prices ranged from $9.41 to $10.55 per share, and the purchases (via family trusts) cost them more than $1.05 million. Shares closed most recently at $9.68, after the San Diego-based biotech announced a license agreement.See also: Insider Sells Best Buy StockAerospace and defense company Heico Corp (NYSE: HEI) saw eight executives and three directors receive 978 shares apiece in accordance with a Leadership Compensation Plan (409A Plan). At about $111.44 apiece, that was worth more than $871,900. Note that a different executive sold more than $2.32 million worth of shares last week. The stock was last seen trading at $112.70 a share.A Citigroup Inc (NYSE: C) director purchased via trust 10,000 shares of this financial services giant last week. At share prices of $44.02 to $44.10, that came to over $440,800 and more than doubled his stake. Note that another director sold fewer than 500 shares last week. The stock fell almost 4% last week to $43.19 a share, despite the company posting solid quarterly results.A director at Carnival Corp (NYSE: CCL) picked up 10,000 shares via trust after the Miami-based cruise line operator canceled more cruises due the extended CDC no-sail order. At around $14.05 per share, that came to nearly $140,500. His stake was listed as shy of 23,800 shares. The stock ended the week at $14.08 per share, just above the purchase price.In addition, some smaller amount of insider buying in Enerpac Tool Group Corp (NYSE: EPAC), Golub Capital BDC Inc (NASDAQ:GDBC), Old Republic International Corporation (NYSE: ORI), Texas Pacific Land Trust (NYSE: TPL) and York Water Co (NASDAQ: YORW) was reported last week as well.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Bulls And Bears Of The Week: Citigroup, Eli Lilly, Ford, GE And More * Barron’s Picks And Pans: eBay, Honeywell, Morgan Stanley And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Morgan Stanley raised their stock price forecast on Netflix to $630 from $600, assigning an “Overweight” rating to the Internet television network’s stock and foresees short and long-term benefits to Netflix growth and earnings power due to the changes brought on by the COVID-19 pandemic.
Using recent actions and grades from TheStreet’s Quant Ratings and layering on technical analysis of the charts of those stocks, Trifecta Stocks identifies five names each week that look bearish and may present interesting investing opportunities on the short side. While we will not be weighing in with fundamental analysis, we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. Guidewire Software Inc. is rated a Hold with a C rating by TheStreet’s Quant Ratings.
Podcast, Google Assistant, Spotify
World news – CA – Google Assistant will play podcasts from third-party services like Spotify